+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasculitis Treatment Market - Global Forecast 2026-2032- Product Image
Vasculitis Treatment Market - Global Forecast 2026-2032- Product Image
New

Vasculitis Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888985
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Vasculitis Treatment Market is undergoing meaningful transformation, driven by clinical innovation, shifting care models, and evolving regulatory landscapes. Senior stakeholders face a dynamic environment with expanding therapeutic options and advancing operational demands.

Market Snapshot: Vasculitis Treatment Market Overview

The global vasculitis treatment market expanded from USD 210.64 million in 2025 to USD 224.74 million in 2026. It is set to sustain growth at a CAGR of 5.59%, and is projected to reach USD 308.45 million by 2032. Growth is propelled by research-driven advances in immunomodulation, the uptake of targeted biologics, and intensifying requirements for multidisciplinary management. Manufacturers, care providers, and procurement teams are navigating new pressures related to supply chain volatility, regulatory adaptation, and the pursuit of differentiated clinical value.

Scope & Segmentation

  • Therapeutic Classes: Biologics, corticosteroids, immunosuppressants, plasma exchange therapies; biologic agents such as rituximab and TNF inhibitors (adalimumab, etanercept, infliximab); immunosuppressants like azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil.
  • Disease Phenotypes: ANCA Associated Vasculitis, Behcet Disease, Giant Cell Arteritis, IgA Vasculitis, Takayasu Arteritis; each with individualized treatment pathways and risk for relapse.
  • Administration Routes: Intravenous, oral, and subcutaneous therapies influence patient adherence, administration site selection, and operational workflow.
  • Care Settings: Ambulatory care centers, clinics, hospitals, and specialty centers, each shaping procurement, monitoring, and service delivery models.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy enable fulfillment, access, and reimbursement alignment.
  • Geographic Focus: Americas, Europe, Middle East & Africa, and Asia-Pacific, each region with distinct regulatory, reimbursement, and manufacturing profiles.

Key Takeaways

  • Clinical practice is reshaping as biologics and refined immunosuppressive protocols reduce dependence on older therapies, driving treatment personalization and safety monitoring.
  • Operational complexity is accelerating through multidisciplinary care models and decentralized access enabled by telehealth, adaptive clinical trials, and infusion-capable outpatient programs.
  • Competitive advantage now hinges on evidence depth, robust patient support systems, and the agility of manufacturers and providers to adapt service delivery and supply chain models.
  • Region-specific approaches are essential, responding to the distinctive regulatory, reimbursement, and logistics challenges in each key market segment.
  • Integrated supply chain strategies and digital adherence tools are emerging as critical investments for sustaining patient access and payer trust amidst increasing financial scrutiny.

Tariff Impact: U.S. Supply Chain and Sourcing Adjustments

Tariff changes in the United States during 2025 have directly influenced the cost structure for biologics and associated consumables. These shifts have required supply chain leaders and commercial strategists to reconsider sourcing models, favoring nearshoring and supplier diversification to preserve cost predictability and treatment continuity. Regulatory and payer responses to these adjustments include updated procurement frameworks and revised formulary tactics for complex therapies. Smaller specialty developers experience differentiated impacts, influenced by supply chain flexibility and the ability to manage cost transitions over time.

Methodology & Data Sources

This analysis is based on primary consultations with clinicians, pharmacy directors, and commercial leaders, complemented by peer-reviewed literature, regulatory directives, and clinical trial registry data. Divergent inputs were reconciled using triangulation and scenario analysis, ensuring balance between clinical realities, operational challenges, and policy shifts.

Why This Report Matters

  • Delivers actionable guidance for optimizing investment across diversified therapeutic portfolios and channel strategies.
  • Supports supply chain and procurement teams in strategic risk management and alignment with regional regulations.
  • Enables decision-makers to benchmark competitive positioning, identify partnership opportunities, and formulate access-centric service models, especially in the face of evolving reimbursement and care delivery trends.

Conclusion

The vasculitis treatment market is defined by rapid therapy innovation, increasing operational complexity, and regionally distinct opportunities. Organizations that combine evidence-driven clinical strategies with flexible, patient-oriented services will be poised to navigate ongoing transformation and improve disease management outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Vasculitis Treatment Market, by Treatment Type
8.1. Biologics
8.1.1. Rituximab
8.1.2. Tumor Necrosis Factor Inhibitors
8.1.2.1. Adalimumab
8.1.2.2. Etanercept
8.1.2.3. Infliximab
8.2. Corticosteroids
8.3. Immunosuppressants
8.3.1. Azathioprine
8.3.2. Cyclophosphamide
8.3.3. Methotrexate
8.3.4. Mycophenolate Mofetil
8.4. Plasma Exchange
9. Vasculitis Treatment Market, by Administration Route
9.1. Intravenous
9.2. Oral
9.3. Subcutaneous
10. Vasculitis Treatment Market, by Disease Type
10.1. ANCA Associated Vasculitis
10.2. Behcet Disease
10.3. Giant Cell Arteritis
10.4. IgA Vasculitis
10.5. Takayasu Arteritis
11. Vasculitis Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Vasculitis Treatment Market, by End User
12.1. Ambulatory Care Centers
12.2. Clinics
12.3. Hospitals
12.4. Specialty Centers
13. Vasculitis Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Vasculitis Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Vasculitis Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Vasculitis Treatment Market
17. China Vasculitis Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Amgen Inc.
18.7. Amneal Pharmaceuticals, Inc.
18.8. Bayer AG
18.9. Bio-Rad Laboratories, Inc.
18.10. Boehringer Ingelheim Pharmaceuticals, Inc.
18.11. Bristol Myers Squibb Company
18.12. ChemoCentryx, Inc.
18.13. DAIICHI SANKYO COMPANY, LIMITED
18.14. F. Hoffmann-La Roche AG
18.15. GlaxosmithKline PLC
18.16. Grifols, S.A.
18.17. InflaRx GmbH
18.18. Johnson & Johnson
18.19. Merck & Co., Inc.
18.20. Novartis AG
18.21. Pfizer Inc.
18.22. Sanofi S.A.
18.23. UCB S.A.
18.24. Vifor Fresenius Medical Care Renal Pharma
List of Figures
FIGURE 1. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL VASCULITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL VASCULITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RITUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY BEHCET DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GIANT CELL ARTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY IGA VASCULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY TAKAYASU ARTERITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 134. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. EUROPE VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 152. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 153. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 154. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 155. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 156. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. AFRICA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 173. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 174. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 175. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. ASEAN VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. GCC VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. GCC VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 179. GCC VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 180. GCC VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 181. GCC VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 182. GCC VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 183. GCC VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 184. GCC VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. GCC VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. BRICS VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. BRICS VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 197. BRICS VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 198. BRICS VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. BRICS VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 200. BRICS VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 201. BRICS VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 202. BRICS VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. BRICS VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. G7 VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. G7 VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 206. G7 VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 207. G7 VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 208. G7 VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 209. G7 VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 210. G7 VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 211. G7 VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. G7 VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. NATO VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. NATO VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 215. NATO VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 216. NATO VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. NATO VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 218. NATO VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 219. NATO VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 220. NATO VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. NATO VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL VASCULITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. CHINA VASCULITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 234. CHINA VASCULITIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 235. CHINA VASCULITIS TREATMENT MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. CHINA VASCULITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 237. CHINA VASCULITIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 238. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 239. CHINA VASCULITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 240. CHINA VASCULITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Vasculitis Treatment market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • ChemoCentryx, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche AG
  • GlaxosmithKline PLC
  • Grifols, S.A.
  • InflaRx GmbH
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • UCB S.A.
  • Vifor Fresenius Medical Care Renal Pharma

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 224.74 Million
Forecasted Market Value ( USD ) by 2032 $ 308.45 Million
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Vasculitis Market - Product Image

Vasculitis Market

  • Report
  • 250 Pages
  • Global
From
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Vasculitis Treatment - Global Strategic Business Report - Product Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Wegener Vasculitis Drug Pipeline Analysis Report 2025 - Product Image

Wegener Vasculitis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Immunoglobulin A IgA Vasculitis Global Market Report 2025 - Product Image

Immunoglobulin A IgA Vasculitis Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Market

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate. In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments. The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.